Skip to main content

Table 5 Short-term efficacy of monotherapy after multi-line chemotherapy

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Short-term efficacy

Number of patients (Percent)

Complete response (CR)

0 (0)

Partial response (PR)

0 (0)

Stable disease (SD)

1 (33.3)

Progressive disease (PD)

2 (66.7)